Get the Stockscreener App
3.26
0.31%
0.010
Kiora Pharmaceuticals Inc stock is traded at $3.26, with a volume of 481.
It is up +0.31% in the last 24 hours and down -9.94% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.25
Open:
$3.22
24h Volume:
481
Relative Volume:
0.01
Market Cap:
$9.77M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.2272
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
+0.31%
1M Performance:
-9.94%
6M Performance:
-10.93%
1Y Performance:
-41.95%
1-Day Range:
$3.22
$3.255
1-Week Range:
$3.07
$3.30
52-Week Range:
$2.91
$6.48
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
781-788-8869
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Compare KPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
3.255 | 9.77M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.12 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.09 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.43 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.57 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.79 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 - MSN
Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria
Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 - StockTitan
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance
January 2025's Top US Penny Stocks To Consider - Yahoo Finance
Kiora Pharmaceuticals, Inc. Announces Promotion of Melissa Tosca to Chief Financial Officer - Marketscreener.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World
3 US Penny Stocks With Market Caps Under $200M - Simply Wall St
US Penny Stocks: 3 Picks With Market Caps Below $400M - Yahoo Finance
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Cerus And 2 Other US Penny Stocks With Promising Potential - Yahoo Finance
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
US Penny Stocks To Watch In January 2025 - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $80M - Simply Wall St
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World
Retinitis Pigmentosa Treatment Market Report: Detailed - openPR
Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail
Persistent Epithelial Defect Market Statistics Expected - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use - Marketscreener.com
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiora Pharmaceuticals Inc Stock (KPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shapiro Aron | Director |
Sep 10 '24 |
Buy |
3.60 |
3,000 |
10,800 |
3,000 |
| Walters-Hoffert Lisa | Director |
Aug 19 '24 |
Buy |
3.86 |
1,250 |
4,825 |
1,250 |
| TYLE PRAVEEN | Director |
Aug 19 '24 |
Buy |
3.96 |
5,000 |
19,800 |
5,014 |
| Tosca Melissa | CFO |
Aug 14 '24 |
Buy |
3.21 |
2,000 |
6,420 |
13,599 |
| Tosca Melissa | EVP Finance |
Jun 14 '24 |
Buy |
5.25 |
100 |
525 |
3,979 |
| Daniels Eric Joseph | Chief Development Officer |
Jun 14 '24 |
Buy |
5.29 |
1,431 |
7,570 |
11,222 |
| Parsons Erin | Director |
Jun 13 '24 |
Buy |
4.88 |
5,260 |
25,669 |
5,260 |
| Strem Brian M. | President and CEO |
Jun 13 '24 |
Buy |
5.00 |
3,000 |
14,997 |
14,531 |
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):